

**Supplementary Figure S1.** Next-generation sequencing of tumor specimens from before (top panels) and after (bottom panels) treatment with savolitinib and osimertinib. **A**, focal *MET* amplification is seen pretreatment (~13 copies) and after resistance (~9 copies). **B**, an *EGFR* exon 19 deletion is also seen pretreatment (22% allelic fraction [AF]) and after resistance (11% AF). **C**, the *MET* D1228V mutation is seen after resistance only (44% AF).

**Supplementary Figure S2.** Expression of D1228V mutation in PC9 cells was confirmed by RT-PCR and cDNA sequencing.